Rosa adds DueDiligienceMD Pharmaceutical Asset Demand Research to ForecastMD market modeling, and AI and Machine Learning capabilities for PhysioPD research.
SAN CARLOS, California, USA, September 14, 2022 /EINPresswire.com/ — As part of our 20th anniversary of providing leadership to biotech and pharmaceutical companies from “Market Entry Mechanism”, and, in response to huge customer demand, Rosa & Co. now offers DueDiligenceMD in addition to our ForecastMD™ Research platform. For innovative organizations that evaluate assets for licensing, partnership, or acquisition, DueDiligenceMD quantifies and explains expected physician demand for an asset based on primary market research and Excel.®income based model. DueDiligenceMD projects are usually completed within two weeks.
To learn more about DueDiligenceMD, watch the webinar titled “Bringing Reality into Commercial Due Diligence for Pharmaceutical Asset Licensing, Partnership or Purchase in Development” with Bill Brastow, Ph.D., CTO of Rosa & Co. OOO in https://rosaandco.com/webinars/2022/injecting-reality-into-the-commercial-due-diligence-process-for-in-licensing-partnering-or-purchasing-pharmaceutical-assets-in-development.
In parallel, Rosa & Co. perfects our best-in-class PhysioPD® Research using artificial intelligence/machine learning (AI/ML) methods strategically. PhysioPD research provides biological context, facilitates understanding of dynamics and causation, and supports hypothesis generation. The addition of AI/ML methods to PhysioPD Research accelerates the identification of networks from data, supports the creation of empirical models and virtual patients, and enriches the information extracted from simulation results.
Details of the new DueDiligenceMD offering and AI/ML methods with PhysioPD Research will be available soon on the Rosa website at www.rosaandco.com. For more information about ForecastMD, DueDiligenceMD, or PhysioPD studies, please contact [email protected]
About Rose and Co.
Rosa & Co. was founded in 2002 to help life sciences companies from Mechanism to Market through its PhysioPD and ForecastMD research platforms.
PhysioPD research is a powerful component of modern drug development. A proven Quantitative Systems Pharmacology (QSP) approach that complements the knowledge and experience of clinicians and research teams, PhysioPD Research provides a more efficient design of experiments and trials and allows for a deeper understanding of empirical data. This study allows for a much more efficient study of the relationship of drugs and disease mechanisms to relevant preclinical and clinical outcomes, supporting more confident decisions at all stages of research and development.
The PhysioPD portfolio pairs beautifully with ForecastMD. Our key ability is to reliably determine which product features will drive physician demand, and how the potential range of product features across those features will compare to current and future competitive options. Our clients use the results of the research to inform internal discussions about new product planning and to inform external discussions with partners and investors regarding the commercial potential of their assets.
For more information please visit www.rosaandco.com.